Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Postoperative pulmonary complications (PPCs) are major causes of postoperative morbidity,
mortality, and prolonged hospital stay.The incidence of PPCs may be as high as 41% to 75% in
high-risk patients. Bronchodilator is frequently used in high-risk patients to prevent PPCs.
Penehyclidine is a new anticholinergic agent which selectively block M1 and M3 receptors. A
previous randomized controlled trial tested the effect of prophylactic penehyclidine
inhalation on the incidence of PPCs in high-risk patients. The purpose of this 3-year
follow-up study is to investigate whether prophylactically penehyclidine hydrochloride
inhalation can affect the 3-year outcomes of patients recruited in the previous randomized
controlled trial.